Vasopressin V1 receptor‐mediated aldosterone production as a result of selective V2 receptor antagonism: a potential explanation for the failure of tolvaptan to reduce cardiovascular outcomes in the EVEREST trial

No abstract is available for this paper.

• Publication year

  2011

• Venue

  European Journal of Heart Failure

• Publication date

  2011-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/eurjhf/hfr150PMID 22102625
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial

  2012cited by this paper
• Plasma aldosterone levels in patients with coronary artery disease without heart failure or myocardial infarction: implications for pathophsiology, prognosis, and therapy.

  2012cited by this paper
• Aldosterone requires vasopressin V1a receptors on intercalated cells to mediate acid-base homeostasis.

  2011cited by this paper
• Eplerenone in patients with systolic heart failure and mild symptoms.

  2011cited by this paper
• Calculated Plasma Volume Status and Mortality in Chronic Heart Failure

  2011cited by this paper
• Hyponatraemia and vasopressin in heart failure: markers or mediators?

  2011cited by this paper
• Renal and Anti-Aldosterone Actions of Vasopressin-2 Receptor Antagonism and B-Type Natriuretic Peptide in Experimental Heart Failure

  2010cited by this paper
• Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice.

  2010cited by this paper
• Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine

  2010cited by this paper
• Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial.

  2009cited by this paper
• Vasopressin regulates the renin-angiotensin-aldosterone system via V1a receptors in macula densa cells.

  2008cited by this paper
• Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.

  2008cited by this paper
• Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial.

  2008cited by this paper
• Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

  2007cited by this paper
• Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.

  2007cited by this paper
• Complementary and Incremental Mortality Risk Prediction by Cortisol and Aldosterone in Chronic Heart Failure

  2007cited by this paper
• Relation between dose of loop diuretics and outcomes in a heart failure population: Results of the ESCAPE Trial

  2007cited by this paper
• Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity

  2007cited by this paper
• Effects of Aldosterone on the Vasculature

  2006cited by this paper
• Mineralocorticoid receptor is overexpressed in cardiomyocytes of patients with congestive heart failure.

  2005cited by this paper
• Furosemide and the progression of left ventricular dysfunction in experimental heart failure.

  2004cited by this paper
• Vasopressin: a new target for the treatment of heart failure.

  2003cited by this paper
• Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD).

  2003cited by this paper
• The Pathophysiology of Aldosterone in the Cardiovascular System

  2002cited by this paper
• Intranephron localization and regulation of the V1a vasopressin receptor during chronic metabolic acidosis and dehydration in rats

  2001cited by this paper
• Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.

  2000cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor.

  1993cited by this paper
• International Journal of Nephrology and Renovascular Disease Dovepress Tolvaptan, Hyponatremia, and Heart Failure

  year unknowncited by this paper

• Tolvaptan treatment in an adult Fontan patient with protein-losing enteropathy: a serial 23Na-MRI investigation

  2021cites this paper
• Adding High-Dose Spironolactone to Tolvaptan Improves Acute Decompensated Heart Failure Due to Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis: A Case Report

  2019influential citation
• Biochemical Determinants of Changes in Plasma Volume After Decongestion Therapy for Worsening Heart Failure.

  2019cites this paper
• Vascular Protection and Decongestion Without Renin-Angiotensin-Aldosterone System Stimulation Mediated by a Novel Dual-Acting Vasopressin V1a/V2 Receptor Antagonist.

  2019cites this paper
• Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial

  2016cites this paper
• Blood Urea Nitrogen/Creatinine Ratio and Response to Tolvaptan in Patients with Decompensated Heart Failure: A Retrospective Analysis

  2015cites this paper
• Hemoconcentration-guided diuresis in heart failure.

  2014cites this paper
• Current treatments for acute heart failure: focus on serelaxin

  2014cites this paper
• Association of Arginine Vasopressin Levels With Outcomes and the Effect of V2 Blockade in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction: Insights From the EVEREST Trial

  2013cites this paper
• [Biomarkers of cardiorenal syndrome].

  2013cites this paper
• Biomarqueurs du syndrome cardiorénal Biomarkers of cardiorenal syndrome

  2013cites this paper
• Association of Arginine Vasopressin Levels with Outcomes and the Effect of V2 Blockade in Patients Hospitalized for Heart Failure with Reduced Ejection Fraction: Insights from the Everest Trial Lanfear Et Al: Avp Levels and Outcomes in Everest

  year unknowncites this paper